Research
Caralluma fimbriata
6 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials.
Systematic review and meta-analysis of clinical trials on Caralluma fimbriata as an appetite suppressant and weight loss supplement. The analysis found significant reductions in waist circumference and waist-to-hip ratio compared to placebo, but no significant effects on body weight, BMI, or appetite parameters. Common side effects included constipation, diarrhea, nausea, and rashes.
The effect of an orally-dosed Caralluma Fimbriata extract on appetite control and body composition in overweight adults.
A double-blind, randomized, placebo-controlled trial examined the effect of Caralluma Fimbriata extract on satiety biomarkers and body composition in 83 overweight adults over 16 weeks. The CFE group showed significant reductions in calorie intake, waist circumference, and maintained body weight compared to the placebo group, which experienced weight gain and increased fat mass.
A randomised placebo controlled clinical trial on the efficacy of Caralluma fimbriata supplement for reducing anxiety and stress in healthy adults over eight weeks.
An 8-week double-blind RCT investigated the efficacy of Caralluma fimbriata extract (CFE) in reducing anxiety and stress in 97 adults with mild to moderate anxiety. The CFE group showed significantly greater reductions in anxiety and stress compared to placebo, with improvements in positive affect and changes in cortisol levels suggesting action through the HPA axis.
Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women.
RCT assessing the effect of Caralluma fimbriata extract on appetite and anthropometry in 50 overweight adults. The experimental group receiving 1 g of Caralluma extract per day showed significant declines in waist circumference and hunger levels compared to placebo over 60 days.
A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial.
This randomized, double-blind, placebo-controlled clinical trial investigated the effect of Caralluma fimbriata extract on metabolic syndrome risk factors in overweight and obese subjects. The experimental group showed significant reductions in waist circumference, waist to hip ratio, body weight, BMI, and systolic blood pressure compared to the placebo group over 12 weeks.
Pharmacological review of Caralluma R.Br. with special reference to appetite suppression and anti-obesity.
Narrative review of Caralluma fimbriata, focusing on its use as an anti-obesity agent and appetite suppressant. The review highlights the presence of pregnane glycosides in Caralluma species, which contribute to its appetite-suppressant properties, and discusses its potential as a nutraceutical.